News
Atossa Therapeutics, Inc. (Nasdaq: ATOS; "Atossa" or the "Company") announced today it has requested a Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss a regulatory strategy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback